SELECTIVE ACYLATION METHOD

Abstract: A method of selectively acylating an insulin, an insulin analogue or a precursor thereof having a free epsilon -amino group of a Lys residue contained therein and at least one free alpha -amino group which method comprises reacting the epsilon -amino group with an activated amide in a polar solvent in the presence of a base.

Description: SELECTIVE ACYLATION METHOD FIELD OF THE INVENTION The present invention relates to a method of introducing an acyl group into a peptide More particularly, the invention relates to an improved method of acylating the ε-amino group of a lysine residue contained in a naturally occurring insulin or an analogue or a precursor thereof BACKGROUND OF THE INVENTION Human insulin and closely related insulins have three primary ammo groups in the molecule namely the α-amino groups of Gly A1 and Phe B1 , respectively, and the ε-amino group of Lys B29 N-Acylation of an unprotected insulin may - depending on the conditions - lead to a complex mixture of mono-, di- and even tπacylated products However, although a certain preference for acylation of a specific position can often be observed the preference is not always sufficiently pronounced to make such direct acylation useful as a method of producing monoacylated insulins since the formation of the desired product may be accompanied by the formation of considerable amounts of closely related by-products When by-products are formed, this happens at the expense of the desired product and may lead to problems in the purification of the desired product Acylation of only one or two specific ammo groups in the insulin molecule can be achieved if a suitably protected intermediate is available A suitable intermediate can be an insulin derivative in which the ammo group(s) not to be acylated is (are) blocked with a protection group which can be removed selectively after the acylation has been performed Such a protected intermediate can either be an insulin precursor or an insulin derivative in which it has been possible to introduce one or two protection groups in a specific way For economic reasons, it is very attractive to avoid the use of specific of protection groups if possible Fnesen HJ et al (Semisynthetic Peptides and Proteins (Offord RE, DiBello C, eds ) 161-179, 1978, London) describe acylation of insulin with N-hydroxysuccimmide esters (in the following referred to as ONSu-esters) and other activated esters under various conditions, as summarised in tables 4 and 5 l.c A certain selectivity is seen but invariably A1 monosubstituted and B29 monosubstituted products are obtained in mixtures with each other and with disubstituted products The highest total yield of monosubstituted products reported is 75% but of this 85% was the A1 isomer in other cases the total yield of monosubstituted products were in the range 45-55% of which 70-72% was the ε-B29 isomer As demonstrated by Fnesen HJ et al (in Chemistry, Structure and Function of Insulin and Related Hormones, Proceedings of the Second International Insulin Symposium (Brandenburg D, Wollmer A, eds ), New York, 1980), the pH of the reaction medium has a very strong influence on the course of the reaction when insulin is acylated with ONSu- esters or certain other acylating agents Thus, at pH 5-6 monoacylation preferably takes place in the B1 am o group and diacylated product will preferably be A1 ,B1-dιacyiated insulin At pH 6 8-9 2 monoacylation preferably takes place in the A1 ammo group while diacylated product can be either A1.B1- or A1,ε-B29-dιacylated insulin Finally, at pH above 10 monoacylation preferably takes place in the ε-amino group of Lys B29 while a further acyl group preferably goes to the ammo group of A1 A method which enables selective acylation of proinsul , insulin or an insulin analogue having a free ε-amino group is disclosed in EP 0 712 861 A2 and EP 0 712 862 A2 (both Eli Lilly and Company) According to the method, unprotected insulins are acylated with soluble, activated fatty acid esters, in particular ONSu-esters, under basic conditions in a polar solvent EP 0 511 600 A2 (Kuraray Co , Ltd ) relates i a to protein derivatives of the formula [proteιn][Z] π wherein [protein] represents a protein having a number of ammo groups, [Z] is a residue represented by the formula -CO-W-COOH wherein W is a divalent long chain hydrocarbon group which may also contain certain hetero atoms and n represents an average of the number of amide bonds between [Z] and [protein] The derivatives are prepared by reaction between the parent protein and a long chain carboxy c acid imide ester in an aqueous solution of a salt optionally also containing an organic solvent No specificity of the acylation is mentioned and the fact that n is stated to be an average number seems to indicate that no specificity is achieved It is mentioned, that insulin is one of the proteins from which derivatives according to the invention can be made, but no specific insulin derivative is disclosed in EP 0 511 600 nor is there any indication of a preferred [Z] or a preferred position in which [Z] should be introduced in order to obtain a useful insulin derivative Examples of insulin derivatives, acylated in the ε-amino group of the Lys residue contained therein, are described in WO 95/07931 (NOVO NORDISK A/S) The derivatives can be produced by acylation of the corresponding (A1 ,B1)-dιBoc insulin, prepared from the corresponding insulin by reaction e g with dι-tert-butyl dicarbonate and subsequently removing the protection groups and by acylation of a single chain insulin precursor which subsequently has to be processed further Surprisingly, it has now been found that high yields of insulins, monoacylated in the ε-amino group of a Lys residue contained therein, can be obtained by the method of the present invention SUMMARY OF THE INVENTION In its broadest aspect, the present invention relates to a method of selectively acylating an insulin, an insulin analogue or a precursor thereof having a free ε-amino group of a Lys residue contained therein and at least one free α-amino group which method comprises reacting the ε-amino group with an activated amide in a polar solvent in the presence of a base DETAILED DESCRIPTION OF THE INVENTION In a preferred embodiment, the parent insulin (i e the naturally occurring insulin, insulin analogue or insulin precursor to be acylated using the method according to the invention) is des(B30) human insulin Examples of other preferred parent insulins are human insulin, porcine insulin and other naturally occurring insulins and also insulin analogues or insulin precursors in which at least one Lys having a free ε-amino group and an ammo acid residue having a free α-amino group is present. One particularly preferred group of parent insulins are insulin analogues in which the am o acid residue in position B1 has been deleted Another particularly preferred group of parent insulins are insulin analogues which have Lys in position B28 and Pro in position B29 A preferred example from this group is Lys B28 Pro B29 human insulin Another particularly preferred group of parent insulins are insulin analogues which have Asp in position B28 A preferred example from this group is Asp 828 human insulin Other particularly preferred groups of parent insulins are insulin analogues in which in which the A-chain and/or the B-chain have an N-terminal extension and insulin analogues in which the A-cham and/or the B-chain have a C-termmal extension Further insulin analogues which can be useful as parent insulins in the method of the present invention are such in which one or more of the ammo acid residues, preferably one, two or three of them, has been substituted by another codable ammo acid residue Thus, in position A21 a parent insulin may in stead of Asn have an ammo acid residue selected from the group comprising Ala, Gin, Glu, Gly, His, lie, Leu, Met, Ser, Thr, Trp, Tyr or Val, in particular an ammo acid residue selected from the group comprising Gly, Ala, Ser and Thr Insulin analogues useful as parent insulins in the method of the present invention may also be modified by a combination of the changes outlined above By "insulin analogue" as used herein is meant a peptide having a molecular structure similar to that of human insulin including the disulphide bridges between Cys A7 and Cys B7 and between Cys* 20 and Cys 819 and an internal disulphide bridge between Cys A6 and Cys A1 \ and which has insulin activity When the ammo acid at position B1 is deleted, the position of the remaining ammo acids of the B-chain are not renumbered The expression "a codable ammo acid residue" as used herein designates an ammo acid residue which can be coded for by the genetic code, / e a triplet ("codon") of nucleotides The preferred parent insulin analogue des(B30) human insulin can be prepared by several methods, i a by enzymatic hydrolysis of human insulin, porcine insulin and insulin derivatives Enzymes that facilitate this hydrolysis are lysyl endopeptidases, such as trypsm and Achromobacter lyticus proteases Furthermore, des(B30) human insulin can be prepared in an enzymatic process from a single chain insulin precursor of the formula B(1-29)-Ala-Ala-Lys-A(1-21) wherein B(1-29) designates the ammo acid sequence from position 1 to position 29 of the B-chain of human insulin and A(1-21) designates the am o acid sequence from position 1 to position 21 of the A-cham of human insulin This precursor can be obtained as described in EP 163 529 A suitable enzyme for the process is Achromobacter lyticus protease 1 , EC code No 34 21 50 The enzyme can be used in a soluble form, or immobilised on a N-hydroxysuccinimide activated Sepharose After completion of the reaction, the des(B30) human insulin formed can be isolated in a number of ways, / a by precipitation by addition of zinc or sodium salts The acylation reaction is usually carried out with a concentration of the parent insulin of from about 0 1% w/w to about 25% w/w, preferably from about 2% w/w to about 12% w/w more preferred from about 3% w/w to about 8% w/w at the beginning of the reaction In one preferred embodiment of the invention, the acyl group to be introduced into the ε- ammo group of a Lys residue is the acyl group of a monocarboxylic acid of the general formula (I) M-COOH (I) wherein M is a long chain hydrocarbon group which may optionally be interrupted by one or more groups each independently selected from the group consisting of an oxygen atom and a sulphur atom More preferred, the acyl group is the acyl group of an unbranched, aliphatic monocarboxylic acid having from 6 to 24 carbon atoms, in particular an acyl group selected from the group comprising CH 3 (CH 2 ) B CO-, CH 3 (CH 2 ) 9 CO-, CH 3 (CH 2 ) 10 CO- T CH 3 (CH 2 )„CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) 13 CO-, CH 3 (CH 2 ) 14 CO-, CH 3 (CH 2 ) 15 CO-, CH 3 (CH 2 ) 16 CO- CH 3 (CH 2 ) 17 CO-, CH 3 (CH 2 ) 18 CO-, CH 3 (CH 2 ) 19 CO-, CH 3 (CH 2 ) 20 CO-, CH 3 (CH 2 ) 21 CO- and CH 3 (CH 2 ) 22 CO- In another preferred embodiment of the invention, the acyl group to be introduced into the ε- ammo group of a Lys residue is one of the acyl groups of a dicarboxy c acid of the general formula (II) HOOC-D-COOH (II) wherein D is a long chain hydrocarbon group which may optionally be interrupted by one or more groups each independently selected from the group consisting of an oxygen atom and a sulphur atom More preferred, the acyl group is one of the acyl groups of a dicarboxylic acid of the general formula (II) wherein D is an unbranched, divalent aliphatic hydrocarbon group having from 6 to 22 carbon atoms, in particular an acyl group selected from the group comprising HOOC(CH 2 ) 6 CO-, HOOC(CH 2 ) B CO-, HOOC(CH 2 ) 10 CO-, HOOC(CH 2 ) 12 CO-, HOOC(CH 2 ) 14 CO-, HOOC(CH 2 ) 16 CO-, HOOC(CH 2 ) 18 CO-, HOOC(CH 2 ) 20 CO- and HOOC(CH 2 ) 22 CO- In further preferred embodiment of the invention, the acyl group to be introduced into the ε- ammo group of a Lys residue is a group of the general formula (III) CH 3 (CH 2 ) x CONHCH(COOR 1 )CH 2 CH 2 CO- (III) wherein x is an integer from 8 to 24 and R 1 is hydrogen or a group which can be exchanged with hydrogen after the acylation has been performed, for example methyl, ethyl or terf-butyl Preferred values of x are 10, 12 and 14 When the acylation has been performed and R 1 is different from hydrogen, the ester group of which R 1 is a part can be hydrolysed to give the corresponding free acid and the alcohol R OH by methods known per se Thus, when R 1 is methyl or ethyl, the hydrolysis can be performed under alkaline conditions and when R 1 is ferf-butyl, the hydrolysis can be carried out using tπfluoroacetic acid In further preferred embodiment of the invention, the acyl group to be introduced into the ε- am o group of a Lys residue is a group of the general formula (IV) lιthocholoyl-NHCH(COOR 2 )CH 2 CH 2 CO- (IV) wherein R 2 is hydrogen or a group which can be exchanged with hydrogen after the acylation has been performed, for example methyl, ethyl or fert-butyl When the acylation has been performed and R 2 is different from hydrogen, the ester group of which R 2 is a part can be hydrolysed to give the corresponding free acid and the alcohol R 2 OH by methods known per se Thus, when R 2 is methyl or ethyl, the hydrolysis can be performed under alkaline conditions and when R 2 is tert-butyl, the hydrolysis can be carried out using tnfluoroacetic acid The acylation of the parent insulin is carried out using an acylating agent which is an activated amide, more particularly an azolide of the acid corresponding to the acyl group to be introduced Such azolides (1-acylazoles) can be prepared according to known methods, see for example Staab HA Angew Chem 74 (1962) 407-423 Examples of azoles which can be used in the preparation of the acylating agents of this invention are pyrazole imidazoie, 1 ,2,3-trιazole, 1 ,2,4-trιazole, tetrazole, phenyltetrazoie and - where possible - the corresponding benzanelated compounds e g 1 H-mdazol, benzimidazole and benzotπazole Preferred azoles for the preparation of the acylating agent are 1 ,2,4-tπazole, benzotπazole and substituted benzotπazoles Optionally, the azoles mentioned can be substituted with one or more substituents selected from the group comprising alkyl (C, - C 5 , branched or unbranched, in particular methyl, ethyl, propyl and isopropyl), halogen (e g fluoro, chloro and bromo, in particular fluoro and chloro), nitro, alkoxy (C, - C 5 , branched or unbranched, in particular methoxy, ethoxy, propoxy and isopropoxy), dialkylated ammo (C, - C 5 , branched or unbranched), sulphonic acid, carboxy and alkoxycarbonyl (C, - C s , branched or unbranched) A preferred group of acylating agents are 1-acyl benzotπazoles and a preferred acylating agent is 1-tetradecanoyl benzotπazoie Other preferred 1-acyl benzotπazoles are such which are derived from mono- or disubstituted benzotnazoles, e g 5-substιtuted or 6-substιtuted or 5,6-dιsubstιtuted benzotnazoles such as 5- methylbenzotπazole, 5-chlorobenzotπazole, 6-chlorobenzotπazole, 5-nιtrobenzotπazole, 5,6- dimethylbenzotπazole and 5,6-dιchlorobenzotrιazole The acylation is carried out in a polar solvent which can be a mixture of water and at least one water-miscible organic solvent Examples of water-miscible solvents which may be useful either alone or in mixtures are lower alcohols, e g methanol, ethanol and 2-propanol, lower straight chain and branched ketones, e g acetone, cyclic ethers, e g tetrahydrofuran and dioxane, straight chain and cyclic amides, e g dimethylformamide, dimethylacetamide and N-methyl-2-pyrrolιdone, nitπles e g acetonitπle and sulfoxides, e g dimethyl sulfoxide Most preferred among the water-miscible organic solvents are N-methyl-2-pyrrotιdone, dimethylformamide, dimethylacetamide and dimethyl sulfoxide The amount of water in the reaction medium may vary within a broad range so that the medium in general contains from about 1% w/w to about 99% w/w of water When N-methyl- 2-pyrro done is used as the water-miscible organic solvent the amount of water in the medium is preferably from about 1% w/w to about 90% w/w, more preferred from about 10% w/w or about 20% w/w to about 75% w/w The acylation is carried out in the presence of an excess of a medium strong or strong base which can be either an inorganic base or an organic base Examples of inorganic bases are sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate Examples of organic bases are tertiary amines, e g ethyldiisopropylamme, tπethylamine and diethylethanolamine Preferably, an organic base is used The amount of base used is generally in excess of 5 mol per mol of parent insulin, e g 10 to 30 mol or even 100 mol of base per mol of parent insulin Basically, the lower limit of the temperature at which the acylation can be carried out is determined by the freezing point of the medium while the upper limit is determined by the temperature at which the parent insulin or the acylated insulin will deteriorate This again will depend / a on the composition of the medium Thus, while it may be possible to carry out the reaction at temperatures between -30 °C and 70 °C it is usually most convenient to carry out the reaction at a temperature between about -5 °C and about 30°C Isolation and purification of the products prepared by the method of the present invention can be carried out by methods known per se, including gel filtration and chromatography The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection The features disclosed in the foregoing description and in the following examples may, either separately or in any combination thereof, be material for realising the invention in diverse forms thereof EXAMPLES Analytical The reaction mixtures - except in Example 4 - were analysed by RP-HPLC as described below using a Merck/Hitachi apparatus equipped with a Diode Array Detector Column 4 0 x 125 mm, operated at 60° Column material dimethyl butyl dimethyl silyl substituted 100 A, 5 mm silica Eluent gradient system Eluent A acetonitnle (7 8%) in water containing ammonium sulphate (2 0%) at pH 2 5 Eluent B acetonitnle (53 9%) in water Flow rate 1 0 ml/mm Detection UV absorption at 280 nm Cycle time 65 mm The yields stated are based on the area of the peaks in the chromatograms The identity of the acylated insulins was determined by their retention time in RP-HPLC and by isolation and mass spectrometry /peptide mapping performed on the acylated products 1 ) without any pre-treatment, 2) after pre-treatment with dithiotreitol for reduction of the disulphide bonds and 3) after pre-treatment with dithiotreitol and Staphylococcus aureus protease V8 for cleavage of the B-chain between position 21 and position 22 Preparation of starting materials: EXAMPLE 1 Preparation of 1-tetradecanoylbenzotrιazole Benzotπazole (59 6 g, 0.50 mol) was dissolved in fert-butyl methyl ether (950 ml) at 20° and tπethylamine (50 6 g, 0 50 mol) was added Tetradecanoyl chloride (125 0 g, 0 51 mol) was added over a period of 30 mm, the temperature being kept at 20-30°C by cooling The resulting precipitate was removed by filtration, and the filtrate evaporated to dryness under reduced pressure at 60°C The residue was dissolved in acetone (375 ml) at 60°C After cooling to 0°C, the resulting crystals were isolated by filtration, washed with acetone (120 ml) and dried to constant weight under reduced pressure at 20°C Yield 142 3 g (86%) of white crystalline 1-tetradecanoylbenzotπazole, melting at 58 0°C (peak value) determined by Differential Scanning Caloπmetry (DSC) Under similar reaction conditions, the following acylated tnazoles were also prepared 1-tetradecanoyl-1 ,2,4-trιazole, DSC 59 7°C (recryst from tetrahydrofuran), 5-methyl-1-tetradecanoylbenzotrιazole, DSC 69 5°C (recryst from 2-propanol), 5-chloro-1-tetradecanoylbenzotrιazole (NMR data seem to indicate that the product also contained some 6-chloro-1-tetradecanoylbenzotrιazole), DSC 52 1°C (recryst from 2- propanol), 5-nιtro-1-tetradecanoylbenzotrιazole, DSC 117 5°C (recryst from acetone), 5,6-dιchloro-1-tetradecanoybenzotrιazole, DSC 60 6°C (recryst from tetrahydrofuran), 5,6-dιmethyl-1-tetradecanoylbenzotrιazole, DSC 61 6°C (recryst from acetone), 1-dodecanoylbenzotπazole, DSC 43 9 β C (recryst from n-heptane) and 1-hexadecanoylbenzotrιazole, DSC 62 4°C (recryst from tert-butyl acetate) EXAMPLE 2 Preparation of 1-(19-carboxynonadecanoyl)benzotπazole A solution of eicosanedioic acid (3 43 g, 10 0 mmol), dicyclohexylcarbodimide (2 06 g, 10 0 mmol), benzotnazole (1 19 g, 10 0 mmol) and dimethylamino-pyπdine hydrochloπde in anhydrous tetrahydrofuran (200 ml) was stirred for two days at room temperature The resulting suspension was filtered, and the filtrate evaporated to dryness under reduced pressure The residue was suspended in dichloromethane (100 ml), and undissolved material was isolated by filtration The dried filter cake (2 0 g) was recrystallised from acetone (200 ml) yielding 0 70 g (16%) of white crystalline 1-(19-carboxynonadecan- oyl)benzotrιazole, melting at 111 9 β C (DSC peak value) EXAMPLE 3 Preparation of 1-(17-carboxyheptadecanoyl)benzotrιazole Under similar reaction conditions as in Example 2, but using octadecanedioic acid in stead of eicosanedioic acid, 1-(17-carboxyheptadecanoyl)-benzotrιazole was prepared The compound had a melting point of 105 2°C (DSC peak value) EXAMPLE 4 Preparation of des(B30) human insulin from a single chain insulin precursor Single chain insulin precursor of the formula B(1-29)-Ala-Ala-Lys-A(1-21) wherein B(1-29) designates the ammo acid sequence from position 1 to position 29 of the B-chain of human insulin and A(1-21 ) designates the ammo acid sequence from position 1 to position 21 of the A-cham of human insulin was obtained as described in EP 163 529 5 g of wet salt cake containing about 1 5 g of the above-mentioned single chain precursor was dissolved in 25 mM sodium hydrogen carbonate (350 ml) at room temperature The pH value of the solution was adjusted to 9 0 by addition of 1 0 M sodium hydroxide (1 ml) Achromobacter lyticus protease 1 , immobilised on N-hydroxysuccinimide activated Sepharose (10 ml of gel with an enzyme density of approximately 1 0 mg/l) was added The reaction mixture was stirred for 23 hours at room temperature and the immobilised enzyme was then removed by filtration The filtrate was analysed by RP-HPLC as described below Based on the area of the peaks in the chromatogram, the relative amount of des(B30) human insulin found in the reaction mixture was 95 2% (retention time 27 7 mm) and the relative amount of starting material was 0 1% (retention time 15 0 mm) Analytical The reaction mixture was analysed by RP-HPLC on equipment supplied by Waters Column 4 0 x 250 mm, operated at 50° Column material YMC 120 A, 5 my OdDMe silylated silica gel Eluent gradient system Eluent A 0 20 M sodium sulphate, 0 04 M phosphoric acid in acetonitnle (10%) in water, pH 2 3 Eluent B acetonitnle (50%) in water Run time 60 minutes Detection UV absorption at 214 nm gradient 00 00 mm 64% A + 36% B 40 00 mm 40% A + 60% B 41 00 mm 64% A + 36% B Preparation of acylated insulins: EXAMPLE 5 Synthesis of N cB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and water (3 5 ml) at 20°C The solution was cooled to 0°C Triethylamine (0 40 ml) was added 1-Tetradecanoylbenzotπazole (1 50 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added over a period of 30 minutes The turbid reaction mixture was stirred at 0°C for 30 minutes, then at 20°C for an additional 30 minutes The reaction mixture was analysed by RP-HPLC with the following results: Retention time, min Compound % yield 11.00 starting material 7.3 25.20 N Λ '-tetradecanoyl des(B30) human insulin 1.8 29.66 N eD "-tetradecanoyl des(B30) human insulin 71.0 49.85 Diacylated des(B30) human insulin 1.1 >50 unknown products totalling 104 EXAMPLE 6 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0.50 g, assay: about 66%~ 0 58 mmol) was dissolved in N- methyl-2-pyrrolιdone (7.5 ml) and water (1.0 ml) at 20°C. Triethylamine (0 40 ml) was added 1-Tetradecanoyl-1 ,2,4-trιazole (1.0 ml of a 0.10 M solution in N-methyl-2- pyrro done) was added in one portion. The homogenous reaction mixture was stirred at 20°C for 10 minutes and then analysed by RP-HPLC with the following results: Retention time, min Compound % yield 11 43 starting material 30 0 25 89 N n ι -tetradecanoyl des(B30) human insulin 8 4 30 37 N c *-"-tetradecanoyl des(B30) human insulin 43 8 50.20 Diacylated des(B30) human insulin 8.7 >50.20 unknown products totalling 3.8 EXAMPLE 7 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0.50 g, assay about 80%~0.070 mmol) was dissolved in dimethyl sulfoxide (7.0 ml) and water (3.5 ml) at 20°C and triethylamine (0.40 ml) was added 1 -Tetradecanoylbenzotπazole (1 80 ml of a 0 10 M solution in N-methyl-2- pyrrohdone) was added over a period of 2 minutes The turbid reaction mixture was stirred at 20°C for 90 minutes The resulting homogeneous reaction mixture was analysed by RP- HPLC showing a yield of 59 4% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 8 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in dimethylformamide (7 0 ml) and 6M aqueous urea (2 0 ml) at 20°C The solution was cooled to 0°C, and triethylamine (0 40 ml) was added 1-Tetradecanoylbenzotrιazole (1 10 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added in one portion The turbid reaction mixture was stirred at 0°C for 60 minutes The resulting slightly turbid reaction mixture was analysed by RP-HPLC showing a yield of 74 2% N cB29 -tetradecanoyl des(B30) human insulin EXAMPLE 9 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and water (2 0 ml) at 20°C The solution was cooled to 0°C Triethylamine (0.20 ml) was added 1-Tetradecanoylbenzotrιazole (1 00 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added in one portion The turbid reaction mixture was stirred at 0°C for 65 minutes The resulting reaction mixture was analysed by RP- HPLC showing a yield of 68 3% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 10 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and 3M aqueous urea (3 5 ml) at 20°C Ethyidnsopropylamine (0 50 ml) was added 1-Tetradecanoylbenzotπazole (1 50 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added over a period of 2 minutes The turbid reaction mixture was stirred at 20°C for 90 minutes The resulting reaction mixture was analysed by RP-HPLC showing a yield of 61 9% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 11 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (5 0 g, assay about 34%~0.30 mmol) was dissolved in N-methyl- 2-pyrrolιdone (20.0 ml) at 20°C After cooling to 0°C, triethylamine (1.50 ml) was added. 5- Nitro-1-tetradecanoylbenzotrιazole (3.20 ml of a 0.10 M solution in N-methyl-2-pyrrolιdone) was added over a period of 10 minutes. The reaction mixture was stirred at 0°C for 30 minutes The resulting reaction mixture was analysed by RP-HPLC showing a yield of 58.3% N εB29 -tetradecanoyl des(B30) human insulin. EXAMPLE 12 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (5.0 g, assay, about 34%~0.30 mmol) was dissolved in N-methyl- 2-pyrrolιdone (20.0 ml) at 20°C. After cooling to 0°C water (7.5 ml) and triethylamine (1.50 ml) was added. 5-Chloro-1-tetradecanoylbenzotrιazole (4.5 ml of a 0.10 M solution in N- methyl-2-pyrrolιdone) was added over a period of 15 minutes. The turbid reaction mixture was stirred at 0 β C for 3 hours. The resulting reaction mixture was analysed by RP-HPLC showing a yield of 77.7% N εB29 -tetradecanoyl des(B30) human insulin. EXAMPLE 13 Synthesis of N εB29 -tetradecanoyl human insulin Human insulin (50 mg, 0.009 mmol) was dissolved in N-methyl-2-pyrrolιdone (0 7 ml) and water (0.35 ml) at 0°C Triethylamine (0.040 ml) was added 1 -Tetradecanoyl- benzotnazole (0 150 ml of a 0.10 M solution in N-methyl-2-pyrrolιdone) was added in one portion The turbid reaction mixture was stirred at 0°C for 150 minutes. The resulting homogeneous reaction mixture was analysed by RP-HPLC showing a yield of 64 0% N tB29 - tetradecanoyl human insulin (retention time: 27.75 min) EXAMPLE 14 Synthesis of N εB29 -tetradecanoyl porcine insulin Porcine insulin (50 mg, 0.009 mmol) was dissolved in N-methyl-2-pyrrolιdone (0.7 ml) and water (0.35 ml) at 0°C Triethylamine (0 040 ml) was added 1 -Tetradecanoyl- benzotπazole (0.150 ml of a 0.10 M solution in N-methyl-2-pyrrolιdone) was added in one portion. The turbid reaction mixture was stirred at 0°C for 155 minutes. The resulting homogeneous reaction mixture was analysed by RP-HPLC showing a yield of 62 5% N εB29 - tetradecanoyl porcine insulin (retention time 28 99 m ) EXAMPLE 15 Synthesis of N εB29 -(19-carboxynonadecanoyl) des(B30) human insulin Des(B30) human insulin (5 0 g, assay about 34%~0 30 mmol) was dissolved in N-methyl- 2-pyrrolιdone (30 0 ml) and water (6 9 ml) at 20°C Triethylamine (1 10 ml) was added 1- (19-carboxynonadecanoyl)benzotrιazole (5 0 ml of a 0 10 M solution in N-methyl-2- pyrrolidone) was added in one portion The reaction mixture was stirred at 20°C for 4 5 hours The resulting reaction mixture was analysed by RP-HPLC showing a yield of 30 0% N εB29 -(19-carboxynonadecanoyl) des(B30) human insulin (retention time 32 19 mm) The amount of starting material was 57 3% EXAMPLE 16 Synthesis of N εB29 -(17-carboxyheptadecanoyl) des(B30) human insulin Under similar reaction conditions as in Example 15, but using 1-(17-carboxyheptadecan- oyl)benzotrιazole in stead of 1-(19-carboxynonadecanoyl)benzotrιazole, the resulting reaction mixture was analysed by RP-HPLC showing a yield of 24 9% N EB 9 -(17- carboxyheptadecanoyl) des(B30) human insulin (retention time 2641 mm) The amount of starting material was 68 3% EXAMPLE 17 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and 3M aqueous urea (3 5 ml) at 20°C Triethylamine (040 ml) was added, and the solution was cooled to -13°C 1-Tetradecanoylbenzotπazole (1 80 mi of a 0 10 M solution in N-methyl-2-pyrrohdone) was added in one portion The resulting suspension was stirred at -13°C for 47 hours The reaction mixture was analysed by RP- HPLC showing a yield of 65 2% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 18 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%~0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and water (2 0 ml) at 20°C The solution was cooled to 0°C Triethylamine (0 40 ml) was added 5-Methyl-1-tetradecanoylbenzotrιazole (1 00 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added in one portion The turbid reaction mixture was stirred at 0°C for 2 hours The resulting solution was analysed by RP-HPLC showing a yield of 66 8% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 19 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (0 50 g, assay about 80%- * -0 070 mmol) was dissolved in N- methyl-2-pyrrolιdone (7 0 ml) and water (2 0 ml) at 20°C Triethylamine (0 40 ml) was added 5,6-Dιchloro-1-tetradecanoylbenzotrιazole (1 10 ml of a 0 10 M solution in N- methyl-2-pyrrolιdone) was added in one portion The turbid reaction mixture was stirred at 20°C for 1 hours The resulting solution was analysed by RP-HPLC showing a yield of 68 8% N cB29 -tetradecanoyl des(B30) human insulin EXAMPLE 20 Synthesis of N εB29 -tetradecanoyl des(B30) human insulin Des(B30) human insulin (5 0 g, assay about 30%~0 26 mmol) was dissolved in N-methyl- 2-pyrrolιdone (30 0 ml) and water (6 0 ml) at 20°C Triethylamine (1 08 ml) was added 5,6-Dιmethyl-1-tetradecanoylbenzotrιazole (4 00 ml of a 0 10 M solution in N-methyl-2- pyrrolidone) was added over a period of 15 minutes The turbid reaction mixture was stirred at 20°C for 1 hours The resulting solution was analysed by RP-HPLC showing a yield of 54 6% N εB29 -tetradecanoyl des(B30) human insulin EXAMPLE 21 Synthesis of N εB29 -dodecanoyl des(B30) human insulin Des(B30) human insulin (0 10 g, assay about 80%~0 014 mmol) was dissolved in N- methyl-2-pyrrolιdone (1 4 ml) and water (04 ml) at 20°C The solution was cooled to 0 β C Triethylamine (0 08 ml) was added 1-dodecanoylbenzotπazole (0 20 ml of a 0 10 M solution in N-methyl-2-pyrrolιdone) was added over a period of 3 minutes The turbid reaction mixture was stirred at 0°C for 40 minutes The resulting solution was analysed by RP-HPLC showing a yield of 58 9% N εB29 -dodecanoyl des(B30) human insulin (retention time 23 17 minutes), and 23 7% of starting material EXAMPLE 22 Synthesis of N εB29 -hexadecanoyl des(B30) human insulin Des(B30) human insulin (0.10 g, assay about 80%~0.014 mmol) was dissolved in N- methyl-2-pyrrolιdone (1 4 ml) and water (04 ml) at 20°C. The solution was cooled to 0°C Triethylamine (0.08 ml) was added 1-hexadecanoylbenzotrιazole (0.20 ml of a 0.10 M solution in N-methyl-2-pyrrolidone) was added over a period of 3 minutes. The turbid reaction mixture was stirred at 0 β C for 60 minutes The still turbid reaction mixture was analysed by RP-HPLC showing a yield of 32 6% N εB29 -hexadecanoyl des(B30) human insulin (retention time 33 41 minutes), and 59 2% of starting material

Claims: CLAIMS 1 A method of selectively acylating an insulin, an insulin analogue or a precursor thereof having a free ε-ammo group of a Lys residue contained therein and at least one free α- ammo group which method compnses reacting the ε-amino group with an activated amide in a polar solvent in the presence of a base 2 The method of claim 1 wherein the insulin is human insulin 3 The method of claim 1 wherein the insulin is porcine insulin 4 The method of claim 1 wherein the parent insulin is an insulin analogue 5 The method of claim 4 wherein the parent insulin is des(B30) human insulin 6 The method of claim 4 wherein the insulin has Lys in position B28 and Pro in position B29 7 The method of claim 4 wherein the insulin is an insulin analogue in which Phe B1 has been deleted 8 The method of claim 4 wherein the insulin is an insulin analogue in which the A-cham and/or the B-chain has an N-termmal extension 9 The method of claim 4 wherein the insulin is an insulin analogue in which the A-cham and/or the B-chain has an C-termmal extension 10 The method of according to any one of the preceding claims wherein the acyl group to be introduced is the acyl group of a monocarboxylic acid of the general formula M-COOH (I) wherein M is a long chain hydrocarbon group which may optionally be interrupted by one or more groups each independently selected from the group consisting of an oxygen atom and a sulphur atom 11 The method of claim 10 wherein the acyl group to be introduced is the acyl group of an unbranched, aliphatic monocarboxylic acid having from 6 to 24 carbon atoms 12 The method of claim 10 wherein the acyl group to be introduced is selected from the group comprising CH 3 (CH 2 ) β CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) 14 CO-, CH 3 (CH 2 ) 16 CO-, CH 3 (CH 2 ) 18 CO-, CH^CH^CO- and CH 3 (CH 2 ) 22 CO- 13 The method of claim 12 wherein the acyl group to be introduced is CH 3 (CH 2 ) 12 CO- 14 The method according to any one of the claims 1-9 wherein the acyl group to be introduced is one of the acyl groups of a dicarboxylic acid of the general formula HOOC-D-COOH (II) wherein D is a long chain hydrocarbon group which may optionally be interrupted by one or more groups each independently selected from the group consisting of an oxygen atom and a sulphur atom 15 The method of claim 14 wherein the acyl group to be introduced is one of the acyl groups of a dicarboxylic acid of the general formula (II) wherein D is an unbranched, divalent aliphatic hydrocarbon group having from 6 to 22 carbon atoms 16 The method of claim 14 wherein the acyl group to be introduced is selected from the group comprising HOOC(CH 2 ) 4 CO-, HOOC(CH 2 ) 6 CO-, HOOC(CH 2 ) 8 CO-, HOOC(CH 2 ) 10 CO-, HOOC(CH 2 ) 12 CO-, HOOC(CH 2 ) 14 CO-, HOOC(CH 2 ) 16 CO-, HOOC(CH 2 ) 18 CO-, HOOC(CH 2 ) 2 oCO- and HOOC(CH 2 ) 22 CO- 17 The method according to any one of the claims 1-9 wherein the acyl group to be introduced is a group of the general formula (III): CH 3 (CH 2 ) x CONHCH(COOR 1 )CH 2 CH 2 CO- (III) wherein x is an integer from 8 to 24 and R 1 is hydrogen or a group which can be exchanged with hydrogen when the acylation has been performed 18 The method of claim 17, wherein x is 10, 12 or 14 19 The method of claim 17, wherein R 1 is methyl, ethyl or tert-butyl 20 The method according to any one of the claims 1-9 wherein the acyl group to be introduced is a group of the general formula (IV) lιthocholoyl-NHCH(COOR 2 )CH 2 CH 2 CO- (IV) wherein R 2 is hydrogen or a group which can be exchanged with hydrogen when the acylation has been performed 21 The method of claim 20, wherein R 2 is methyl, ethyl or tert-butyl 22 The method according to any one of the preceding claims, wherein the acylation is carried out using an acylating agent which is an azolide of the acid corresponding to the acyl group to be introduced 23 The method of claim 22, wherein the azolide is derived from an azole selected from the group comprising pyrazole, imidazole, 1 ,2,3-tπazole, 1 ,2,4-trιazole, tetrazole and phenyl- tetrazole 24 The method of claim 22, wherein the azolide is derived from a benzanelated azole 25 The method of claim 22, wherein the azolide is derived from an azole selected from the group comprising mdazole, benzimidazole and benzotnazole 26 The method of claim 22, wherein the acylating agent is 1 -tetradecanoyl benzotπazoie 27 The method of claim 22, wherein the azolide is derived from a benzotnazole which is mono- or disubstituted with a substituent selected from the group comprising C r C 4 alkyl, halogen and nitro 28 The method of claim 27, wherein the azolide is derived from the group comprising 5- methylbenzotπazole, 5-chlorobenzotrιazole, 5-nιtrobenzotπazole, 5,6-dιmethylbenzotπazole and 5,6-dιchlorobenzotπazole 29 The method according to any one of the preceding claims, wherein the organic solvent is selected from the group comprising N-methyl-2-pyrrolιdone, dimethylformamide, dimethylacetamide and dimethyl sulfoxide 30 The method according to any one of the preceding claims, wherein the medium contains from about 1% w/w to about 99% w/w of water 31. The method according to any one of the preceding claims, wherein the solvent is N- methyl-2-pyrroiidone containing from about 1% w/w to about 90% w/w, preferably from about 20% w/w to about 75% w/w of water.

Inventors: HANSEN LOUIS BRAMMER, HANSEN, LOUIS, BRAMMER
Applicants: HANSEN LOUIS BRAMMER, NOVONORDISK AS, HANSEN, LOUIS, BRAMMER, NOVO NORDISK A/S
Application year: 1997
Main classification: C07K14
IPC codes: A61K38, C07K1, C07K14